CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
Kidney International Reports - United States
doi 10.1016/j.ekir.2016.08.019
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 1, 2017
Authors
Publisher
Elsevier BV